Audited Financial Results and recommendation of final dividend for financial year 2025-26
NEULANDLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Neuland Laboratories reported strong full-year results for FY 2025-26. Consolidated revenue grew 37% to Rs 2,02,299 lakhs from Rs 1,47,684 lakhs the prior year, driven by robust growth across Europe and the US. PAT surged approximately 40% to Rs 36,400 lakhs from Rs 26,011 lakhs, while EPS stood at Rs 283.71 (consolidated). The Board recommended a final dividend of Rs 34 per share (340%). An exceptional gain of Rs 7,640.36 lakhs from the transfer of an investment property was recorded in the prior year and excluded from ongoing earnings. The company also announced a Rs 143.4 crore capacity expansion at its Unit 1 to be funded through internal accruals and borrowings, with utilisation already at 91%. Statutory auditors MSKA & Associates LLP issued an unmodified (clean) opinion on both standalone and consolidated results. Dr. Mauricio Futran was appointed as an Additional Director (Non-Executive, Non-Independent).
Strong top-line and bottom-line growth with clean audit opinion and a healthy dividend payout signal positive sentiment for investors. The capacity expansion indicates management confidence in sustained demand growth, particularly from export markets.